fig2
![Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma](https://image.oaes.cc/dd5ae343-cfb2-49f8-963c-986305c80cde/3577.fig.2.jpg)
Figure 2. Overall survival from BVZ administration calculated by Kaplan-Meier curves for 31 patients stratified by: (A) NLR positive or negative; (B) PLR positive or negative; (C) Association between NLR and PLR. It seems the more NLR increases, the more PLR increases as well. This association is almost statistically significant following a Spearman test (P > 0.05; 95%CI). BVZ: bevacizumab; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio